Of the 9.2 million doses of vaccine injected to date, 20,260 cases of side effects were reported by the regional pharmacovigilance centers at the National Medicines Safety Agency (ANSM). Or 0.2%. Of these cases, 4,863 were considered “serious”.
Since February 6, 7,439 cases of side effects have been identified after an injection of the AstraZeneca vaccine, making this solution the one recording the most cases. But in view of the number of doses injected (2.5 million), this is very low, barely 0.3 cases per 100 doses administered.
26% of cases of side effects are considered “serious” by the ANSM. But this rate is very probably overestimated, many non-serious side effects not being reported by the vaccinated people.
Second on the podium, the vaccine from Pfizer, with 12,249 cases recorded, or 0.2 cases per 100 doses. Moderna’s solution brings up the rear, with 577 cases (0.08%).
A total of 91 cases of severe thromboembolic events were analyzed for AstraZeneca vaccine. Or 0.003% of the injected doses, which remains extremely rare. The problems observed are not banal thromboses (formation of blood clots preventing blood circulation) but a singular phenomenon: “thromboses of the large veins, atypical by their location (mainly cerebral, but also digestive), which may be associated with thrombocytopenia [un déficit en plaquettes sanguines, NDLR] or bleeding disorders ”.
An investigation has been opened by the European Medicines Agency to verify possible links between the administration of the vaccine and these events. The Amsterdam-based agency’s security committee “has yet to come to a conclusion and the review is ongoing,” EMA said in a statement, adding that a decision on the matter is expected to be announced. Wednesday or Thursday.
For the vaccine from the German-American laboratory Pfizer, 89 cases of thromboembolic events were identified. An almost identical number as for the AstraZeneca. 37 were during the last week but, underlines the ANSM, “this could potentially be related to the recent media coverage of these events with the AstraZeneca vaccine because, among the new cases reported, a majority concerned cases that occurred several weeks ago ”.
No cases have been recorded with the Moderna vaccine. Not surprisingly, the vaccine having been injected only 675,000 times, against a few million more than the other two.
So far, most cases with AstraZeneca are people under 65 (96%), mostly women (74%). But no conclusion can be drawn from this since this vaccine was initially mainly used on young populations and by women, health professions, priority category, being very feminized.
“For the moment, the examinations have not identified specific risk factors for these very rare events such as age, gender or a medical history including blood clot problems,” confirms the European Medicines Agency.
The majority of influenza-like illnesses are still reported. 48 severe cases of elevated blood pressure also occurred. Effects that are found in the other two vaccines in circulation in France.
As of January 20, 2021, 34 people who have been vaccinated with the AstraZeneca vaccine have died, 354 with Pfizer and none with Moderna. But the National Medicines Safety Agency (ANSM) affirms that “the current data do not allow to conclude [que ces décès] are linked to vaccination ”.
The risks of thrombosis and side effects remain extremely rare and exceptionalregardless of the vaccine. In other words, you are more likely to get a severe or fatal form of covid-19 than a similar form from a vaccine solution.
This is why the European Medicines Agency confirms that the benefit-risk balance remains positive. The UK Medicines Agency confirms this advice: “The benefits of the AstraZeneca vaccine continue to far outweigh the risks and the public should continue to receive the vaccine when instructed to do so. “
Support a professional editorial staff at the service of Brittany and the Bretons: subscribe from € 1 per month.